Compare CVS Health Corp (CVS) vs Xylem, Inc. (XYL) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

Xylem (XYL) trades at $120.32, down 0.36% on the day, with a neutral technical signal and key support at $120. The company reported strong Q2 2026 earnings of $1.46 per share, beating estimates, and raised its full-year profit guidance. Revenue growth has been steady, reaching $9.04B in 2025, with net income margins improving to 10.59%. Analyst sentiment is mixed, with a consensus price target of $150.43, implying significant upside from current levels.

The outlook for XYL is positive, driven by robust demand in water technology and AI infrastructure, alongside margin expansion. Key risks include project delays in electric metering and competitive pressures. With a P/E of 28.65, the stock trades at a premium, but continued execution on earnings and strategic acquisitions supports a constructive view for long-term investors.